Gorlin syndrome and desmoplastic medulloblastoma

Report of 3 cases with unfavorable clinical course and novel mutations

Sridharan Gururangan, Giles Robinson, David W. Ellison, Gang Wu, Xuelian He, Q. Richard Lu, Roger Mclendon, Gerald Grant, Timothy Driscoll, Ronnie Neuberg

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We present three cases of genetically confirmed Gorlin syndrome with desmoplastic medulloblastoma (DMB) in whom tumor recurred despite standard therapy. One patient was found to have a novel germline missense PTCH1 mutation. Molecular analysis of recurrent tumor using fluorescent in situ hybridization (FISH) revealed PTEN and/ or PTCH1 loss in 2 patients. Whole exome sequencing (WES) of tumor in one patient revealed loss of heterozygosity of PTCH1 and a mutation of GNAS gene in its non-coding 3' -untranslated region (UTR) with corresponding decreased protein expression. While one patient died despite high-dose chemotherapy (HDC) plus stem cell rescue (ASCR) and palliative radiotherapy, two patients are currently alive for 18+ and 120+ months respectively following retrieval therapy that did not include irradiation. Infants with DMB and GS should be treated aggressively with chemotherapy at diagnosis to prevent relapse but radiotherapy should be avoided. The use of molecular prognostic markers for DMB should be routinely used to identify the subset of tumors that might have an aggressive course.

Original languageEnglish (US)
Pages (from-to)1855-1858
Number of pages4
JournalPediatric Blood and Cancer
Volume62
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Basal Cell Nevus Syndrome
Medulloblastoma
Mutation
Neoplasms
Radiotherapy
Exome
Drug Therapy
Germ-Line Mutation
Loss of Heterozygosity
3' Untranslated Regions
Missense Mutation
Fluorescence In Situ Hybridization
Stem Cells
Recurrence
Therapeutics
Genes
Proteins

Keywords

  • Clinical features
  • Gorlin syndrome
  • Medulloblastoma
  • Mutation
  • PTCH
  • Whole genome sequencing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Gururangan, S., Robinson, G., Ellison, D. W., Wu, G., He, X., Lu, Q. R., ... Neuberg, R. (2015). Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations. Pediatric Blood and Cancer, 62(10), 1855-1858. https://doi.org/10.1002/pbc.25560

Gorlin syndrome and desmoplastic medulloblastoma : Report of 3 cases with unfavorable clinical course and novel mutations. / Gururangan, Sridharan; Robinson, Giles; Ellison, David W.; Wu, Gang; He, Xuelian; Lu, Q. Richard; Mclendon, Roger; Grant, Gerald; Driscoll, Timothy; Neuberg, Ronnie.

In: Pediatric Blood and Cancer, Vol. 62, No. 10, 01.10.2015, p. 1855-1858.

Research output: Contribution to journalArticle

Gururangan, S, Robinson, G, Ellison, DW, Wu, G, He, X, Lu, QR, Mclendon, R, Grant, G, Driscoll, T & Neuberg, R 2015, 'Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations', Pediatric Blood and Cancer, vol. 62, no. 10, pp. 1855-1858. https://doi.org/10.1002/pbc.25560
Gururangan, Sridharan ; Robinson, Giles ; Ellison, David W. ; Wu, Gang ; He, Xuelian ; Lu, Q. Richard ; Mclendon, Roger ; Grant, Gerald ; Driscoll, Timothy ; Neuberg, Ronnie. / Gorlin syndrome and desmoplastic medulloblastoma : Report of 3 cases with unfavorable clinical course and novel mutations. In: Pediatric Blood and Cancer. 2015 ; Vol. 62, No. 10. pp. 1855-1858.
@article{97a7b6e78c6e418eadaaaaca79309b47,
title = "Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations",
abstract = "We present three cases of genetically confirmed Gorlin syndrome with desmoplastic medulloblastoma (DMB) in whom tumor recurred despite standard therapy. One patient was found to have a novel germline missense PTCH1 mutation. Molecular analysis of recurrent tumor using fluorescent in situ hybridization (FISH) revealed PTEN and/ or PTCH1 loss in 2 patients. Whole exome sequencing (WES) of tumor in one patient revealed loss of heterozygosity of PTCH1 and a mutation of GNAS gene in its non-coding 3' -untranslated region (UTR) with corresponding decreased protein expression. While one patient died despite high-dose chemotherapy (HDC) plus stem cell rescue (ASCR) and palliative radiotherapy, two patients are currently alive for 18+ and 120+ months respectively following retrieval therapy that did not include irradiation. Infants with DMB and GS should be treated aggressively with chemotherapy at diagnosis to prevent relapse but radiotherapy should be avoided. The use of molecular prognostic markers for DMB should be routinely used to identify the subset of tumors that might have an aggressive course.",
keywords = "Clinical features, Gorlin syndrome, Medulloblastoma, Mutation, PTCH, Whole genome sequencing",
author = "Sridharan Gururangan and Giles Robinson and Ellison, {David W.} and Gang Wu and Xuelian He and Lu, {Q. Richard} and Roger Mclendon and Gerald Grant and Timothy Driscoll and Ronnie Neuberg",
year = "2015",
month = "10",
day = "1",
doi = "10.1002/pbc.25560",
language = "English (US)",
volume = "62",
pages = "1855--1858",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Gorlin syndrome and desmoplastic medulloblastoma

T2 - Report of 3 cases with unfavorable clinical course and novel mutations

AU - Gururangan, Sridharan

AU - Robinson, Giles

AU - Ellison, David W.

AU - Wu, Gang

AU - He, Xuelian

AU - Lu, Q. Richard

AU - Mclendon, Roger

AU - Grant, Gerald

AU - Driscoll, Timothy

AU - Neuberg, Ronnie

PY - 2015/10/1

Y1 - 2015/10/1

N2 - We present three cases of genetically confirmed Gorlin syndrome with desmoplastic medulloblastoma (DMB) in whom tumor recurred despite standard therapy. One patient was found to have a novel germline missense PTCH1 mutation. Molecular analysis of recurrent tumor using fluorescent in situ hybridization (FISH) revealed PTEN and/ or PTCH1 loss in 2 patients. Whole exome sequencing (WES) of tumor in one patient revealed loss of heterozygosity of PTCH1 and a mutation of GNAS gene in its non-coding 3' -untranslated region (UTR) with corresponding decreased protein expression. While one patient died despite high-dose chemotherapy (HDC) plus stem cell rescue (ASCR) and palliative radiotherapy, two patients are currently alive for 18+ and 120+ months respectively following retrieval therapy that did not include irradiation. Infants with DMB and GS should be treated aggressively with chemotherapy at diagnosis to prevent relapse but radiotherapy should be avoided. The use of molecular prognostic markers for DMB should be routinely used to identify the subset of tumors that might have an aggressive course.

AB - We present three cases of genetically confirmed Gorlin syndrome with desmoplastic medulloblastoma (DMB) in whom tumor recurred despite standard therapy. One patient was found to have a novel germline missense PTCH1 mutation. Molecular analysis of recurrent tumor using fluorescent in situ hybridization (FISH) revealed PTEN and/ or PTCH1 loss in 2 patients. Whole exome sequencing (WES) of tumor in one patient revealed loss of heterozygosity of PTCH1 and a mutation of GNAS gene in its non-coding 3' -untranslated region (UTR) with corresponding decreased protein expression. While one patient died despite high-dose chemotherapy (HDC) plus stem cell rescue (ASCR) and palliative radiotherapy, two patients are currently alive for 18+ and 120+ months respectively following retrieval therapy that did not include irradiation. Infants with DMB and GS should be treated aggressively with chemotherapy at diagnosis to prevent relapse but radiotherapy should be avoided. The use of molecular prognostic markers for DMB should be routinely used to identify the subset of tumors that might have an aggressive course.

KW - Clinical features

KW - Gorlin syndrome

KW - Medulloblastoma

KW - Mutation

KW - PTCH

KW - Whole genome sequencing

UR - http://www.scopus.com/inward/record.url?scp=84939571693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939571693&partnerID=8YFLogxK

U2 - 10.1002/pbc.25560

DO - 10.1002/pbc.25560

M3 - Article

VL - 62

SP - 1855

EP - 1858

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 10

ER -